Skip to main content
FishtownFish wrapped around the rod of AsclepiusMedicine
Preventive Primary Care
How Care Works
Virtual & Home Visits
Virtual care across 40 states + house calls in Philadelphia
Concierge vs. Direct Care
Zero visit copays, zero hidden fees, relationship model
Send Medical Records
Securely upload prior labs & notes before consultation
Common Questions (FAQ)
PCP scope, insurance, labs & cancellation policies
Services
Primary Care & Acute Visits
Same-day sick visits, refills & comprehensive PCP care
Chronic & Complex Care
POTS, MCAS, Long COVID, Lyme & fatigue workups
Hormones & Endocrine
TRT, thyroid, perimenopause, menopause & PCOS
Metabolic Health & Weight
Advanced lipid testing, GLP-1s & glucose monitoring
Longevity & Prevention
Medicine 3.0 baselines, VO2 max, DEXA & prevention
All Clinical Services
Comprehensive catalogue of 36+ clinical services
Membership
Membership Details
Unlimited direct access, continuous physician care
Care Packages
The Reset & Strategic Roadmap evaluations
Billing & Payment FAQ
HSA/FSA eligibility, transparent cancellation policy
About
Meet Dr. Ash
Your Physician
GER·O·SPAN
Our Clinical Framework
Clinical Library & Articles
Evidence-based health guides reviewed by Dr. Ash
What People Say
124 patient reviews across 6 platforms
Contact Dr. Ash
Reach out with questions or book an intro
Patient PortalStart Intake
The 'Widowmaker' Genetic Risk Factor
Fishtown Medicine•8 min read

The 'Widowmaker' Genetic Risk Factor

Ashvin Vijayakumar MD

Medically Reviewed

Ashvin Vijayakumar MD•Updated October 17, 2026
On This Page
  • Why do lean, fit 45-year-olds with "normal" cholesterol still have heart attacks?
  • Why do standard checkups skip Lp(a) - and why is that a mistake?
  • How do we cut cardiovascular risk by 50 to 65% when Lp(a) is high?
  • Where do the new Phase 3 Lp(a) drugs stand after September 2026?
  • Actionable Steps in Philly
  • ✦Key Takeaways
  • Common Questions
  • Can statins lower Lp(a)?
  • Why is niacin (Vitamin B3) bad for Lp(a)?
  • Should I take 81 mg baby aspirin if my Lp(a) is over 50 mg/dL?
  • What happened with the new Lp(a) drugs in 2026?
  • What units are used to report Lp(a)?
  • Do I need a Coronary CT Angiogram (CCTA) if my Lp(a) is high?
  • Deep Questions
  • How does Lp(a) drive plaque and aortic valve stenosis differently than LDL?
  • Why is PCSK9 inhibition so valuable in high-Lp(a) patients?
  • How does Fishtown Medicine treat high Lipoprotein(a)?
  • How often does Fishtown Medicine retest Lipoprotein(a)?
  • Scientific References
  • Related at Fishtown Medicine

Get a preventive doctor that knows you.

Consult Dr. Ash
TL;DR30-second take

Lipoprotein(a), said L-P-little-A, is a genetic cholesterol particle (>= 50 mg/dL or >= 125 nmol/L in 1 in 5 adults) that drives heart attacks, ischemic strokes, and aortic valve narrowing. Standard cholesterol panels leave it off. We test every adult once in nmol/L, and when Lp(a) is high, we cut global cardiovascular event risk by 50 to 65% by driving ApoB below 50 mg/dL, keeping blood pressure under 120/80 mmHg, holding hs-CRP below 1.0 mg/L, imaging the coronary arteries early, and personalizing low-dose aspirin.

TL;DR:

  • 1 in 5 adults carry it silently: Lipoprotein(a) (Lp(a) >= 50 mg/dL or >= 125 nmol/L) is an inherited, sticky cholesterol particle that causes premature heart attacks, strokes, and calcific aortic valve stenosis even when your standard LDL cholesterol looks "normal."12
  • How we cut high-Lp(a) risk by 50 to 65% today: In EPIC-Norfolk (n = 17,087) and the UK Biobank (n = 385,917), Lp(a) multiplies the danger of ApoB, blood pressure, and inflammation (hs-CRP). Driving ApoB < 50 mg/dL, blood pressure < 120/80 mmHg, and hs-CRP < 1.0 mg/L eliminates 50 to 65% of the excess cardiovascular risk.345
  • PCSK9 inhibitors pull double duty: In the FOURIER (n = 25,096) and ODYSSEY OUTCOMES (n = 18,924) trials, PCSK9 inhibitors (evolocumab, alirocumab) reduced Lp(a) by 19 to 30% while lowering ApoB and LDL-C by 50 to 60%, cutting major cardiovascular events by 23% (NNT = 40) in high-Lp(a) patients.67
  • Aspirin and niacin precision: Low-dose aspirin (81 mg) cuts events by 56 to 76% in LPA rs3798220-C variant carriers (WHS and ASPREE trials) and is favored when CAC >= 100 or soft plaque is present, whereas pooled cohorts (n = 23,662) show no blanket benefit from mass Lp(a) level alone (HR 1.01).8910 Never use niacin: it failed in HPS2-THRIVE (n = 25,673) and creates the vascular-toxic metabolite 4PY.1112
  • The Phase 3 drug pipeline: After pelacarsen's Lp(a)HORIZON (~80% reduction) missed its primary 4-point MACE endpoint in September 2026, all eyes are on olpasiran (OCEAN(a)-Outcomes, 94-97% reduction, due late 2026), lepodisiran (ACCLAIM-Lp(a), due 2029), and oral muvalaplin (MOVE-Lp(a), due 2031).131415

Why do lean, fit 45-year-olds with "normal" cholesterol still have heart attacks?

Standard lipid panels measure LDL-C cholesterol mass and skip Lipoprotein(a) (Lp(a)). Roughly 20% of adults inherit high Lp(a) (>= 50 mg/dL or >= 125 nmol/L), a triple-threat particle that builds plaque, oxidizes artery walls, and blocks clot breakdown even when standard LDL is normal.12

Someone 45 years old, a marathon runner who eats well and looks as lean and healthy as anyone in the room, has a sudden heart attack on Kelly Drive. Every routine cholesterol panel that person ever had came back "normal." Almost every time a story is shaped like that one, Lipoprotein(a) is what was driving it.12

Picture the Vine Street Expressway (I-676) at rush hour, and picture your coronary arteries the same way:

  • ApoB is the total traffic volume: Put enough cars on the road and you get traffic jams - inside an artery wall, that is atherosclerotic plaque.
  • Lp(a) is an ApoB particle carrying a sticky, pro-clotting protein tail (apolipoprotein(a)) plus oxidized phospholipids (OxPL): Even when traffic is light, Lp(a) snags the artery wall, pulls immune cells in via OxPL inflammation, and mimics plasminogen so your body's clot-dissolving crew cannot clear micro-clots smoothly.12

Particle-for-particle, Mendelian randomization data from the European Atherosclerosis Society show that an Lp(a) particle is roughly 6 times more atherogenic than a standard LDL particle - and it also deposits calcium directly into the aortic heart valve, driving aortic valve stenosis.1

High Lp(a) Action Plan Today & The Phase 3 Drug Pipeline

Why do standard checkups skip Lp(a) - and why is that a mistake?

For decades, routine checkups skipped Lp(a) because 80 to 90% of your level is genetically fixed at birth and diet or statins do not lower the Lp(a) number itself. That logic is backwards: knowing your Lp(a) tells us how aggressively to lower your modifiable ApoB, blood pressure, and hs-CRP, which cuts your measured heart attack risk by 50 to 65%.1345

Multiple international guidelines (2022 European Atherosclerosis Society, 2024 National Lipid Association Focused Update, and 2026 ACC/AHA) now recommend measuring Lp(a) at least once in every adult's lifetime, preferably in nmol/L (particle concentration) instead of mg/dL (mass), because apo(a) tail sizes vary widely from person to person.116

Lp(a) Risk TierParticle Count (nmol/L - Preferred)Mass Unit (mg/dL)Clinical Meaning
Optimal / Normal< 75 nmol/L< 30 mg/dLNo added genetic Lp(a) hazard; manage ApoB to standard preventive target (< 60-70 mg/dL).
Borderline / Gray Zone75 to 124 nmol/L30 to 49 mg/dLModest risk amplifier; tighten ApoB (< 60 mg/dL) and check family history.
High Risk (1 in 5 Adults)>= 125 nmol/L>= 50 mg/dLCausal risk enhancer; drive ApoB < 50 mg/dL, BP < 120/80, hs-CRP < 1.0 mg/L, image early (CCTA/CAC), and cascade-test family.116
Very High / Extreme>= 200 to 250 nmol/L>= 90 to 100 mg/dL2- to 3-fold lifetime MI and aortic stenosis risk; often pair statin + ezetimibe with a PCSK9 inhibitor and early CCTA.16

How do we cut cardiovascular risk by 50 to 65% when Lp(a) is high?

Because Lp(a) acts multiplicatively with ApoB, blood pressure, and vascular inflammation (hs-CRP), crushing those modifiable substrates defangs most of Lp(a)'s absolute risk right now - before any Lp(a)-specific drug is FDA-approved.34517

Large prospective cohorts prove that you are not a prisoner of your Lp(a) gene:

  • The EPIC-Norfolk 20-Year Study (Verbeek 2018 & Kraaijenhof 2025, n = 17,087): Having 1, 2, or all 3 markers high (LDL-C, hs-CRP, and Lp(a)) raised cardiovascular events stepwise (HR 1.33, 1.68, and 2.41), and when LDL-C was kept below 2.5 mmol/L (~97 mg/dL), the excess hazard of Lp(a) at or above the 80th percentile dropped substantially.35
  • The UK Biobank (Wang et al., 2025, n = 385,917) & Life's Simple 7 (Razavi 2025): High-Lp(a) adults who achieved optimal global cardiovascular health (Life's Simple 7 >= 10) had a ~65% lower ASCVD event rate (HR 0.35) than high-Lp(a) adults with poor modifiable metrics, and combined LDL-C + Lp(a) lowering cut coronary risk by ~51%.418
Marker / Risk LeverStandard Lab "Normal"Fishtown Target When Lp(a) >= 125 nmol/LClinical Trial & Cohort Evidence
ApoB (Total Plaque Particles)LDL-C < 100 mg/dLApoB <= 60 mg/dL (< 50 mg/dL when plaque is present)Across 6 statin trials (Bhatia 2025) + FOURIER (O'Donoghue 2019), driving ApoB/LDL down cuts absolute MACE across all Lp(a) tiers; PCSK9i adds a 19-30% Lp(a) drop (NNT = 40).6717
Blood Pressure< 140/90 (or < 130/80)< 120/80 mmHg on home cuffEliminates endothelial shear stress where sticky Lp(a) particles enter the artery wall (Razavi 2025: -65% ASCVD risk with optimal global metrics).18
hs-CRP (Vascular Inflammation)< 3.0 mg/L< 1.0 mg/LQuiets oxidized phospholipid (OxPL) signaling that turns Lp(a) plaques unstable (Kraaijenhof 2025).3
Low-Dose Aspirin (81 mg)Rarely discussed with Lp(a)Targeted shared decision (CAC >= 100, soft plaque, or rs3798220-C carrier + low bleed risk)Cuts MACE 56 to 76% in LPA rs3798220-C carriers (WHS & ASPREE), while pooled mass-only cohorts (n = 23,662) show HR 1.01 without genotype or plaque selection.8910
Niacin (Vitamin B3)Sometimes peddled for -20% Lp(a)Do NOT use (Contraindicated)Failed in HPS2-THRIVE (n = 25,673, RR 0.96), raises diabetes (+32%) and bleeding (+38%), and produces vascular-toxic 4PY (Ferrell Nat Med 2024).1112

Where do the new Phase 3 Lp(a) drugs stand after September 2026?

In September 2026, the first Phase 3 cardiovascular outcomes trial - Lp(a)HORIZON (n = 8,323) testing monthly pelacarsen (~80% Lp(a) reduction) - reported that it did not meet its primary 4-point MACE endpoint.13 Three next-generation Phase 3 programs are still underway:

  • Olpasiran (OCEAN(a)-Outcomes, n = 7,297, expected ~December 2026): Quarterly siRNA injection that lowers Lp(a) deeper (94 to 97%) in patients with Lp(a) >= 200 nmol/L and uses a focused 3-point coronary endpoint.1314
  • Lepodisiran (ACCLAIM-Lp(a), n = 17,300, due March 2029): Twice-yearly siRNA (~94% reduction) enrolling both secondary-prevention and high-risk primary-prevention patients (Lp(a) >= 175 nmol/L).15
  • Muvalaplin (MOVE-Lp(a), n = 10,450, due March 2031): The first daily oral pill that blocks Lp(a) particle assembly (~86% intact-assay reduction).19

For the full breakdown of all four trials, read our dedicated guide to the new Lp(a)-lowering drugs.

Actionable Steps in Philly

Use these four If -> Then triggers to turn a one-time genetic blood test into lifelong protection:

  1. If you have never had Lp(a) checked -> order Lp(a) in nmol/L on your next blood draw: You only need to run this test once in your life (~$40 cash at Quest or LabCorp), and if you are a woman, recheck once after menopause when levels can rise by 15 to 25%.116
  2. If your Lp(a) comes back >= 70 to 125 nmol/L -> drive your ApoB to 60 mg/dL or under (< 50 mg/dL if very high): Combine nutrition with low-dose hydrophilic statin + ezetimibe, and add a PCSK9 inhibitor (evolocumab or alirocumab) when needed to trim Lp(a) 19 to 30% and drop ApoB 50 to 60%.67
  3. If you are over 40 with high Lp(a) -> look at your arteries directly (CCTA or CAC) and personalize 81 mg aspirin: Because 11 to 16% of US adults with CAC = 0 still carry non-calcified soft plaque - particularly when Lp(a) is high - a standard Coronary CT Angiogram (CCTA) (~$400 to $450 cash) or CAC scan tells us whether to add 81 mg daily aspirin (favored when CAC >= 100, soft plaque is visible, or LPA rs3798220-C is positive).8916
  4. If your Lp(a) is high -> cascade-test your parents, siblings, and children: Lp(a) is inherited in an autosomal codominant pattern, giving first-degree relatives a ~50% chance of carrying high Lp(a) that a routine checkup will never catch.116
✦

Key Takeaways

  1. Test Once in nmol/L: Levels are 80 to 90% genetically fixed for life (>= 125 nmol/L or >= 50 mg/dL is high risk).1
  2. Crush Global Risk (-50 to 65% events): Drive ApoB to 60 mg/dL or under (< 50 mg/dL when plaque is present), BP < 120/80 mmHg, and hs-CRP < 1.0 mg/L while avoiding niacin fully.31112
  3. Cascade Screen & Watch the Aortic Valve: First-degree relatives have a 50% chance of inheriting high Lp(a), and older adults with very high Lp(a) should have their aortic valve monitored for calcification.1

Scientific References

  1. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946. PMID: 36036785.
  2. Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48-e60. PMID: 34647487.
  3. Kraaijenhof JM, et al. Twenty-Year Cardiovascular Risk Associated With Combined Elevation of LDL Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) in EPIC-Norfolk. Eur Heart J. 2025. PMID: 40167249.
  4. Wang M, et al. Joint associations of lipoprotein(a) and low-density lipoprotein cholesterol with incident coronary artery disease in 385,917 UK Biobank participants. Int J Epidemiol. 2025. PMID: 40064167.
  5. Verbeek R, Hoogeveen RM, Langsted A, et al. Cardiovascular disease risk associated with high lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. Eur Heart J. 2018;39(27):2589-2596. PMID: 29931232.
  6. O'Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial. Circulation. 2019;139(12):1483-1492. PMID: 30586750.
  7. Schwartz GG, Ballantyne CM, Barter PJ, et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome (ODYSSEY OUTCOMES). J Am Coll Cardiol. 2021;78(5):421-433. PMID: 34325831.
  8. Chasman DI, Shiffman D, Zee RYL, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy in the Women's Health Study. Atherosclerosis. 2009;203(2):371-376. PMID: 18775538.
  9. Lacaze P, Bakshi A, Riaz M, et al. Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes (ASPREE). J Am Coll Cardiol. 2022;80(14):1287-1298. PMID: 36175048.
  10. Colantonio LD, et al. Aspirin use and cardiovascular events among adults with high lipoprotein(a): a pooled analysis of ARIC, CHS, and MESA. Eur J Prev Cardiol. 2025. PMID: 40874494.
  11. HPS2-THRIVE Collaborative Group; Landray MJ, Haynes R, Hopewell JC, et al. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. N Engl J Med. 2014;371(3):203-212. DOI: 10.1056/NEJMoa1300955.
  12. Ferrell M, Wang Z, Anderson JT, et al. A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk. Nat Med. 2024;30(2):424-434. DOI: 10.1038/s41591-023-02793-8.
  13. Parcha V, Bittner VA. Lipoprotein(a)-Lowering Therapies in Clinical Trials: From Antisense Oligonucleotides to siRNAs and Oral Small Molecules. Curr Atheroscler Rep. 2026. DOI: 10.1007/s11883-026-01474-4.
  14. O'Donoghue ML, Rosenson RS, Gencer B, et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease (OCEAN[a]-DOSE). N Engl J Med. 2022;387(20):1855-1864. DOI: 10.1056/NEJMoa2211023.
  15. Nissen SE, Ni W, Shen X, et al. Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a). N Engl J Med. 2025;392(17):1673-1683. DOI: 10.1056/NEJMoa2415818.
  16. Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18(3):e308-e319. PMID: 38565461.
  17. Bhatia HS, et al. Independent and Additive Cardiovascular Risk of Lipoprotein(a) and LDL Cholesterol Across Six Randomized Statin Trials. Circulation. 2025. PMC: PMC11771346.
  18. Razavi AC, et al. Ideal Cardiovascular Health Attenuates Lipoprotein(a)-Associated Atherosclerotic Cardiovascular Disease Risk. Diabetes Obes Metab. 2025. DOI: 10.1111/dom.16469.
  19. Nicholls SJ, Ni W, Rhodes GM, et al. Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial (KRAKEN). JAMA. 2025;333(3):222-231. DOI: 10.1001/jama.2024.24017.

Related at Fishtown Medicine

  • 9-System Biomarker Reference Guide: Optimal vs Standard Lab Ranges - how Lp(a), ApoB, hs-CRP, and fasting insulin targets fit together across all 9 systems
  • Lowering Lp(a): The New Phase 3 Drugs - full breakdown of Lp(a)HORIZON, OCEAN(a)-Outcomes, ACCLAIM-Lp(a), and MOVE-Lp(a)
  • Borderline Cholesterol: How ApoB, Lp(a), and Blood Pressure Change the Plan - a patient case where 3 unmeasured numbers turned "recheck in a year" into a plan
  • Stroke Prevention in Philadelphia - the 2024 AHA/ASA guideline applied across BP, GLP-1, diet, CRF, and insulin resistance
  • ApoB and Heart Health - the cholesterol particle count that predicts heart attacks far better than standard LDL
  • Lp(a) and Cholesterol - why you can have perfect cholesterol and still be at high risk
  • Coronary Calcium Score (CAC) vs. CCTA - when CAC = 0 still misses non-calcified plaque in high-Lp(a) adults
  • Heart Disease in Women - Lp(a) is one of the risks a standard calculator for women leaves out
  • High Triglycerides: What Your Number Means and What To Do - another advanced lipid marker worth checking alongside Lp(a)
Ashvin Vijayakumar MD (Dr. Ash)

Fishtown Medicine | Cardiovascular risk

2418 E York St, Philadelphia, PA 19125·(267) 360-7927·hello@fishtownmedicine.com·HSA/FSA Eligible

Start Your Intake
Medical Disclaimer: This resource provides clinical context for educational purposes. In the world of Precision Medicine, there is no "one size fits all" - the right plan must be matched to your unique lab work, physiology, and goals. Consult Dr. Ash to determine if this approach is right for you, particularly if you have chronic health conditions or are taking prescription medications.

Frequently Asked Questions

Common Questions

No - statins do not lower Lp(a) and can slightly raise it (5 to 15%). However, patient-level data across 6 randomized statin trials (Bhatia et al., Circulation 2025) confirm that statins significantly lower heart attacks in high-Lp(a) patients by removing the ApoB particles that Lp(a) multiplies.<sup>17</sup>
Although niacin drops Lp(a) by 20 to 25% on a lab test, it failed to reduce heart attacks or strokes in AIM-HIGH and HPS2-THRIVE (n = 29,087), increased new-onset diabetes (+32%) and major bleeding (+38%), and produces a metabolite called 4PY that directly inflames blood vessels via VCAM-1 (Ferrell et al., Nature Medicine 2024).<sup>11</sup><sup>12</sup>
It depends on your genotype, your coronary plaque burden, and your bleeding risk. In randomized trials (WHS and ASPREE), low-dose aspirin cut cardiovascular events by 56 to 76% in carriers of the LPA rs3798220-C genetic variant,<sup>8</sup><sup>9</sup> whereas a 2025 pooled analysis of 23,662 adults (ARIC, CHS, MESA) found no overall benefit (HR 1.01) when selecting by Lp(a) >= 50 mg/dL mass level alone.<sup>10</sup> We favor 81 mg aspirin when high Lp(a) is paired with CAC >= 100, non-calcified plaque on CCTA, or rs3798220-C carrier status and low bleeding risk.<sup>16</sup>
In September 2026, pelacarsen (~80% Lp(a) reduction) missed its primary 4-point MACE endpoint in Lp(a)HORIZON (n = 8,323).<sup>13</sup> Three deeper reducers remain in Phase 3 outcome trials: olpasiran (OCEAN(a)-Outcomes, 94-97% reduction, due late 2026), lepodisiran (ACCLAIM-Lp(a), due 2029), and oral muvalaplin (MOVE-Lp(a), due 2031).<sup>13</sup><sup>14</sup><sup>15</sup><sup>19</sup>
Lp(a) is reported either in nmol/L (particle concentration - preferred) or mg/dL (mass). Because the apo(a) protein tail contains a variable number of kringle-IV repeats (KIV-2), mass assays in mg/dL can over- or under-estimate particle count. Thresholds are 75 nmol/L (30 mg/dL) for borderline risk and 125 nmol/L (50 mg/dL) for high risk.<sup>1</sup><sup>16</sup>
After age 40 (or earlier with a family history of premature heart disease), a standard Coronary CT Angiogram (CCTA) or Coronary Calcium Score (CAC) is one of the highest-yield tests you can run. High Lp(a) accelerates non-calcified soft plaque before calcium shows up on a CAC scan, and seeing the artery wall directly tells us whether to push ApoB below 40 to 50 mg/dL and add 81 mg aspirin.<sup>16</sup>

Deep-Dive Questions

Lp(a) is a triple threat: (1) its apoB-100 core deposits cholesterol into the artery wall just like LDL; (2) its apo(a) kringle domains carry oxidized phospholipids (OxPL) that trigger intense IL-6/TNF-alpha inflammation in artery walls and osteogenic calcification in aortic valve leaflets; and (3) its structural homology to plasminogen competitively inhibits tissue plasminogen activator (tPA), slowing fibrinolysis (clot breakdown).<sup>1</sup><sup>2</sup>
Unlike statins, PCSK9 monoclonal antibodies (evolocumab and alirocumab) lower Lp(a) by 19 to 30% while slashing ApoB and LDL-C by 50 to 60%.<sup>6</sup><sup>7</sup> In FOURIER (O'Donoghue et al., Circulation 2019, n = 25,096), patients with baseline Lp(a) above the median (37 nmol/L) achieved a 23% relative risk reduction in MACE (HR 0.77) and an absolute 3-year NNT of 40 (compared with NNT = 105 in low-Lp(a) patients).<sup>6</sup>
Fishtown Medicine considers Lipoprotein(a) optimal under 30 nmol/L, and when Lp(a) is high (above all at or above 70 nmol/L), treats it by tightening every modifiable cardiovascular risk factor around it: driving ApoB to 60 mg/dL or under, keeping blood pressure below 120/80, and optimizing fasting insulin and HbA1c.
Fishtown Medicine typically tests Lipoprotein(a) once as part of a baseline cardiovascular workup, because Lp(a) levels are determined by genetics and stay stable across adulthood.

Ready when you are

Start your intake

The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.

Related Intelligence

ApoB vs LDL: Why Your "Normal" Cholesterol Score Might Be Misleading

ApoB vs LDL: Why Your "Normal" Cholesterol Score Might Be Misleading

A guide to ApoB vs LDL and why a normal cholesterol report can still hide serious heart risk. From a Medicine 3.0 practice in Philadelphia.

Read Deep Dive
Preventive Cardiology Philadelphia | ApoB & Lp(a) Testing

Preventive Cardiology Philadelphia | ApoB & Lp(a) Testing

Standard cholesterol panels miss most heart attacks. See how a Philadelphia preventive cardiology approach uses ApoB, Lp(a), and modern imaging to catch risk early.

Read Deep Dive
Healthspan vs Lifespan: Why Living Longer Is Not Enough | Philadelphia

Healthspan vs Lifespan: Why Living Longer Is Not Enough | Philadelphia

Americans live to about 78 but spend the last 12 years sick and dependent. A Philadelphia primary care practice on why healthspan is the better metric.

Read Deep Dive

New patients

Talk it through with Dr. Ash.

Share your numbers if you know them, your family history, and what you want to get ahead of. Dr. Ash reads every intake personally.

HSA/FSA eligible
No initiation or cancellation fees
No copays
Tell Dr. Ash what’s going on →
FishtownFish wrapped around the rod of AsclepiusMedicine
Preventive Primary Care
2418 E York St, Philadelphia, PA 19125(267) 360-7927Primary care in PhiladelphiaHome visits in Greater PhiladelphiaPricing & MembershipGER·O·SPAN: our clinical frameworkDigital Health LiteracyClinical Evidence & Research

Serving Fishtown · Northern Liberties · East Kensington · Olde Richmond · Port Richmond · Old City · Callowhill · Poplar · Center City · Center City West · Art Museum · Bella Vista · Chestnut Hill · Fairmount · Fitler Square · Graduate Hospital · Logan Square · Manayunk · Queen Village · Rittenhouse · Roxborough · Society Hill · Southwark · Bryn Mawr, PA · Gladwyne, PA · Villanova, PA · Wayne, PA · Cherry Hill, NJ · Haddonfield, NJ · Medford, NJ · Moorestown, NJ · Voorhees, NJ

Explore by topic

Women’s Health
  • Perimenopause
  • Menopause 3.0
  • PCOS
  • Fertility
Men’s Health
  • Testosterone (TRT)
  • Sleep Apnea & Low T
  • Andropause
  • Low Libido
Metabolic
  • Medical Weight Loss
  • Ozempic vs Metformin
  • Fasting Protocols
  • Visceral Fat
Cardiovascular
  • apoB & Heart Health
  • apoB vs LDL
  • Lp(a) Cholesterol
  • ED & Heart Risk
Longevity + Performance
  • Healthspan vs Lifespan
  • Biological Age
  • VO2 Max
  • Zone 2 Training
Supplements
  • Magnesium
  • Creatine
  • Omega-3
  • Foundational Stack
  • Supplement Guides
Care in Philadelphia +
Direct Primary Care in Philadelphia, PAConcierge Medicine in Philadelphia, PAConcierge vs DPC in Philadelphia, PALongevity Medicine in Philadelphia, PAPreventive Care in Philadelphia, PAExecutive Physical in Philadelphia, PAAnnual Physical in Philadelphia, PAHealthspan Optimization in Philadelphia, PAFunctional Medicine in Philadelphia, PASame-Day Sick Visits in Philadelphia, PATestosterone Replacement Therapy in Philadelphia, PAPerimenopause Care in Philadelphia, PAMenopause Care in Philadelphia, PAThyroid Treatment in Philadelphia, PAPCOS Care in Philadelphia, PAGLP-1 Weight Loss in Philadelphia, PAMetabolic Health in Philadelphia, PAHormone Optimization in Philadelphia, PAAdvanced Lipid Testing in Philadelphia, PAVO2 Max Testing in Philadelphia, PADEXA Scan in Philadelphia, PACGM in Philadelphia, PALong COVID Care in Philadelphia, PAChronic Fatigue Treatment in Philadelphia, PAPOTS Treatment in Philadelphia, PAMCAS Treatment in Philadelphia, PALyme Disease Care in Philadelphia, PABrain Fog Treatment in Philadelphia, PASleep Disorders Treatment in Philadelphia, PAStrep Throat Treatment in Philadelphia, PAUTI Treatment in Philadelphia, PASinus Infection Treatment in Philadelphia, PASTI Testing in Philadelphia, PATravel Medicine in Philadelphia, PAPre-Op Clearance in Philadelphia, PASports Club Medicine in Philadelphia, PA

Made it this far? You’re already most of the way there. let’s get started → Dr. Ash reads every word personally.

Content is for educational purposes only and does not constitute medical advice.

TermsPrivacyScope of PracticeClinical IndependenceCare NetworkResearch & Monographs